OCON Therapeutics

Executive Summary

OCON Therapeutics is an Israeli med-tech company pioneering a novel intrauterine ball-shaped device (IUB®) made from Nitinol. The IUB platform offers hormone-free contraception and localized drug delivery for women’s health conditions such as abnormal uterine bleeding, endometriosis, and fibroids. By replacing the traditional T-shaped IUD design with a spherical shape, OCON aims to improve patient comfort, safety, and efficacy. The company has raised $10 million to date and is currently in Phase 2 clinical development. Its differentiated approach addresses significant unmet needs in contraception and gynecological therapies, positioning it as a potential disruptor in the women's health market. With a strong focus on safety and patient experience, OCON's technology could capture substantial market share if clinical data confirm its advantages.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 clinical data readout for IUB contraception60% success
• Q3 2026FDA pre-IDE meeting or IDE submission for IUB endometriosis trial70% success
• H2 2026Strategic licensing or distribution partnership for European markets50% success